Rebus Holdings, Inc. (RBSH)
OTCMKTS: RBSH · Delayed Price · USD
0.0120
0.0000 (0.00%)
May 23, 2022 12:00 AM EDT - Market closed
| Market Cap | 385,594 |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 2.09M |
| Shares Out | 32.13M |
| EPS (ttm) | 0.68 |
| PE Ratio | 0.02 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0000 |
| Previous Close | 0.0120 |
| Day's Range | 0.0000 - 0.0000 |
| 52-Week Range | 0.0070 - 0.1200 |
| Beta | -14.08 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | n/a |
About RBSH
Rebus Holdings, Inc. focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. The company was founded in 2003 and is based in Westlake Village, California.
IndustryBiotechnology
Founded2003
Employees1
Stock ExchangeOTCMKTS
Ticker SymbolRBSH
News
Inspyr Therapeutics Secures $500,000 to Support the Development of its Adenosine Pipeline
Proceeds support the development of lead asset, RT-AR001, an adenosine receptor antagonist Funds were secured from an existing institutional investor WESTLAKE VILLAGE, CA / ACCESSWIRE / January 12, 2021...
1 year ago - Accesswire